Bard Implanted Port Catheter
Centralized before Judge David G. Campbell in the District of Arizona in August 2023, the Bard Implanted Port Catheter litigation consolidates federal claims alleging that implanted chemotherapy port catheters manufactured by Bard are defectively designed or manufactured in a way that makes them prone to fracture, migrate, or otherwise fail once implanted, causing infection and internal injury in cancer patients who depend on the devices for treatment access. With 3,734 actions pending, the docket has grown into one of the larger active medical-device mass torts in the federal system.
This litigation has already moved meaningfully past the general-causation-uncertainty phase that defines many newer dockets: a bellwether trial produced a $40 million jury verdict for the plaintiff, and a third bellwether trial is scheduled for October 2026. That sequencing — an established bellwether process generating an actual verdict, followed by additional trials to test how consistently that result holds — is a classic signal of a docket transitioning from causation-development toward a phase where the parties, and the court, have real data to evaluate whether a coordinated resolution framework is more efficient than continued individual trials.
What continues to drive duration and resolution risk for the claims still open is less whether the core defect theory can succeed — the first bellwether verdict suggests it can — and more how individualized causation and damages questions resolve across a claimant population defined by cancer treatment, where comorbidities and pre-existing conditions can complicate causation arguments case by case. The outcome of the October 2026 bellwether trial will be a significant marker for whether this docket is approaching a global resolution framework or continuing toward a longer series of individual trials. Criterica Intelligence's platform tracks this bellwether-to-resolution trajectory across every active MDL, offering a structural read on pace and posture without predicting the outcome of any individual trial or claim.
A bellwether trial produced a $40 million verdict for the plaintiff, and a third bellwether trial is scheduled for October 2026 — evidence the docket has moved past its general-causation-uncertainty phase.
It signals that the core defect theory can succeed before a jury, though it does not resolve individualized causation and damages questions, which still vary claim by claim across the pending population.
Its outcome will help indicate whether the parties are approaching a global resolution framework or continuing toward a longer series of individual trials, depending on how consistent the results are with the first verdict.
Absent settlement, individual cases are generally remanded to their originating federal districts for further pretrial proceedings and trial once centralized bellwether work concludes.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.